Form 4: Tarsus General Counsel Sells Shares for Tax Obligations

Tarsus Pharmaceuticals' General Counsel, Bryan Wahl, sold common stock to cover tax withholding obligations from RSU vesting.

Summary

• Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, Inc. (TARS), disposed of common stock.
• The sales occurred on March 17, 2026, March 18, 2026, and March 19, 2026.
• A total of 12,440 shares were sold across these three dates.
• The shares were sold at prices ranging from $67.00 to $69.42 per share.
• The transactions were 'sell to cover' sales, mandated by the Issuer to satisfy tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).
• These sales were not discretionary transactions by the Reporting Person.
• Following these transactions, Bryan Wahl beneficially owns 63,959 shares of Tarsus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The reported transactions are routine 'sell to cover' sales for tax purposes, not discretionary sales, and therefore do not indicate a change in management's confidence or the company's fundamentals.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a standard practice for executives receiving equity compensation, such as Restricted Stock Units (RSUs), to meet tax liabilities upon vesting. These non-discretionary sales are common across various industries, particularly in high-growth sectors like pharmaceuticals where equity compensation is a significant component of executive pay.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are non-discretionary sales for tax purposes, which are common and generally not indicative of a change in company outlook or insider sentiment.

Key Dates

Recommendation

The filing details a routine 'sell to cover' transaction by an insider to satisfy tax obligations upon RSU vesting. This is a non-discretionary event and does not reflect a change in the company's operational performance, strategic direction, or the insider's discretionary view of the stock's future prospects. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Bryan Wahl, General Counsel